Eli Lilly received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for obesity treatment. The drug represents the first oral GLP-1 approved specifically for weight management, marking a significant milestone in obesity therapeutics.
Foundayo was approved under the FDA's Commissioner's National Priority Voucher program in just 50 days after filing, making it the fastest new molecular entity approval since 2002. The accelerated timeline reflects the FDA's recognition of the urgent need for effective obesity treatments.